Background: We have previously shown that suppression of Interleukin-2 (IL-2) secretion was mediated by transforming growth factor (TGF) [51 secreted by small-cell lung cancer (SCLC) tumor cells. We have also shown that IL-2 secretion was significantly impaired in patients with SCLC at the time of diagnosis. Reconstitution of cytokine secretion correlated with reduction of tumor load. These data suggested that the immune system was suppressed by the tumor. To address the clinical relevance of cytokine suppression in SCLC, we investigated the correlation of the level of IL-2 secretion with survival.
Introduction
We have previously reported that cytokine secretion is selectively suppressed in patients with SCLC at the time of diagnosis [1] . Compared to normal controls, immunocompetent cells from patients with SCLC secreted significantly lower amounts of IL-2, IFN-a, IFN-y, and TNF-oc upon mitogen stimulation. Secretion of IL-l-a and IL-l-P was not significantly suppressed. Cytokine secretion substantially improved upon successful reduction of tumor load by chemotherapy but not upon ineffective cytostatic treatment [1] , These results suggested a suppression of the immune system by the tumor that may have clinical significance. In further studies, we have identified an immunosuppressive factor secreted by SCLC cell lines as transforming growth factor (TGF) pi [2, 3] . We found that TGF pi induces the same selective cytokine suppression as seen in SCLC patients [1, 2, 4] . Thus, several lines of evidence suggested that TGF pi secreted by SCLC cell lines might play a role in clinical disease. TGF pi might therefore represent the factor that mediates the immunosuppressive interaction between tumor cells and the immune system.
Based on these data, we speculated that suppression of IL-2 secretion at the time of diagnosis may influence survival. Therefore, we analysed the correlation between IL-2 secretion at the time of diagnosis and the clinical course of the disease. We found that reduction of IL-2 secretion is strongly correlated with survival time in patients with SCLC. Several parameters have been established as prognostic factors for SCLC. Among these, stage of disease, performance status, NSE, LDH, histologic subtype, age, and sex were shown to be of clinical importance [5] [6] [7] [8] [9] . We performed univariate and multivariate analyses to establish the relative prognostic value of IL-2 secretion compared to these factors.
Patients and methods

Patients
Blood samples were taken from 58 patients with histologically confirmed SCLC (36 limited disease, mean age 62 years, range 37-71 years, 22 extensive disease, mean age 61 years, range 36-77 years) during the time of diagnosis, prior to any treatment. All patients had a good performance status with a Karnofsky-Index of 70% to 100%. Fifty-two patients received standard treatment including chemotherapy and radiation when clinically indicated. Six patients were not treated with cytostatic drugs and were therefore not included in our analysis. Mean age of all 52 patients included in this study was 58 years (range 36-75). Assessment of blood chemistry including measurement of lactate dehydrogenase (LDH) and neurone specific enolase (NSE) was performed according to standard procedures.
Blood samples and whole blood cell culture Between 8 and 10 a.m., 10 ml of heparinized blood were taken from patients during the initial staging and used for further investigations within two hours. Differential leucocyte counts were determined from the same venous puncture.
Heparinized venous blood was used according to the method described [1, 10, 11] . Briefly, blood was diluted 1:5 with RPM1-1640 medium (GIBCO Laboratories, Grand Island, NY, USA) supplemented with HEPES (10 mM final concentration), L-glutamine (2 mM final concentration), penicillin (100 U/ml), and streptomycin (100 ug/ ml).
Stimulation of cytokine secretion and determination of cytokine concentrations
Stimulation of cytokine secetion was performed as previously described [1, 10, 11] . Briefly, cells were incubated in 96 well plates at a final volume of 200 ul culture medium at 37 °C and 5% CO 2 in humified air and stimulated for 48 hours in the presence of 10 ug/ml PHA for the secretion of IL-2. Supernatants were tested for the presence of IL-2 by using an enzyme-linked-immunosorbent-assay (ELISA) as previously described [1, 4] . Briefly, cytokines of the standard and the cell supernatants were bound to a murine monoclonal antibody that previously had been absorbed to the bottom of a microtiter plate. A second murine monoclonal antibody against the cytokine conjugated with peroxidase was added. After an incubation time of 16-24 hours the peroxidase activity was determined by a redox indicator. The intensity of the color measured with a multi-channel photometer is directly proportional to the cytokine concentration Assay range is 20-1000 pg/ml for IL-2.
Statistical analysis
The significance of correlations between single parameters in the test groups was calculated by using the linear regression analysis, the Wilcoxon rank sum test [12] , and the exact test according to Fisher [13] . Survival was calculated using the method according to Kaplan and Meier [14] , The significance of differences between subgroups was calculated using the log-rank test [15] . /"-values < 0.05 were considered significant. For the multivariate analysis of prognostic factors, the coxmodel [16] with a multiphasic evaluation strategy [17] was used. For the evaluation of proportional hazard functions empiric log plots and the acceleration test [18] were used. The best cut-off value was defined as the one that best discriminated between good and poor prognosis [19] .
Results
IL-2 secretion in SCLC at the time of diagnosis
IL-2 secretion was assessed in whole blood cell cultures from 52 patients with SCLC as previously reported [1] . Of these 52 patients, 33 had limited disease (LD) and 19 had extensive disease (ED). Overall response was obtained in 39 patients (75%), including 15 complete remissions (28.8%) and 24 partial remissions (46.1%). Thirteen patients (25%) did not respond to chemotherapy. Mean IL-2 secretion in 33 SCLC, LD, and 19 SCLC, ED at the time of diagnosis was 1530 pg/ml (95% CI 995-2065) and 1251 pg/ml (95% CI 823-1678), respectively.
Survival in SCLC in correlation to IL-2 secretion
Overall survival of all 52 patients is shown in Figure 1 . Survival in correlation to the amount of IL-2 secretion is shown in Figure 2 . The best cut-off value was defined as the one that best discriminated between good and poor prognosis. The cut-off value for IL-2 secretion was found to be 1550 pg/ml. Our results demonstrate that IL-2 secretion significantly influences survival in SCLC patients. In the group of patients with an amount of IL-2 1550 pg/ml, survival was significantly reduced com- 
Correlation and multivariate analysis
Several parameters have been established as prognostic factors for SCLC. Among these, stage of disease, performance status, NSE, LDH, histologic subtype, age, and sex were shown to be of clinical importance, although not all these factors are generally accepted prognostic factors. To establish the relative prognostic value of IL-2 secretion compared to these factors, we first analysed the influence of prognostic factors shown in Table 1 on survival. In the univariate analysis, the influence of tumor stage on survival was significant with a P-value of 0.006 ( Figure 3 , Table 1 ). As expected, patients with SCLC limited disease (LD) had a significantly better survival than patients with extenxive disease (ED). The influence of NSE on survival was significant with a /•-value of 0.003 ( Figure 4 , Table 1 ). The The significance of differences between subgroups was calculated using the log-rank test. The best cut-off value for IL-2 secretion, NSE, LDH, age was defined as the one that best discriminated between good and poor prognosis.
influence of LDH on survival was significant with a Pvalue of 0.012 (Table 1 ). The influence of LDH on survival was not independent from NSE ( Table 2) .
The influence of age and sex on survival was not significant in our patient population (P = 0.063 and 0.063, respectively) ( Table 1 ). The influence of histological subtype (oat cell type or intermediate cell type) on survival was not significant (P -0.551) ( Table 1) . In this study, only patients with a performance status according to a Karriofsky-index of 7O°/c^lOO% were included. Therefore, as expected, the influence of performance status on survival was not significant in our patient population (P = 0.242) (data not shown).
Using the Wilcoxon rank sum test and the linear regression analysis, IL-2 secretion was not correlated to the stage of disease, NSE, LDH, sex, or age. The NSElevel was correlated to stage of disease and to LDH ( Table 2) .
Cox regression analysis of factors related to survival was performed to identify which independent factors might jointly have a significant influence on survival. In the first step of the multivariate analysis, only factors with significant prognostic impact in the univariate analysis and independent from other factors were included. Thus, LDH was excluded from multivariate analysis for dependence from NSE. Furthermore, NSE and stage of disease were not found to be independent factors. Nevertheless, as both factors are currently considered as the most important prognostic factors except from performance status, they were included in independent multivariate analyses in correlation to IL-2 secretion. Our analysis demonstrated that after the last step of the Cox-regression analysis (final model) for IL-2 secretion and stage of disease, P-values for IL-2 secretion and stage of disease were 0.012 and 0.019, respectively (Table 3) .
After the last step of the cox-regression analysis (final model) for IL-2 secretion and NSE, P-values for IL-2 and NSE were 0.02 and 0.021, respectively (data not shown). These data show that IL-2 secretion has a predominant prognostic value for survival in SCLC that is comparable to the value of already established prognostic factors.
Discussion
We found that the capacity of immunocompetent cells to secrete IL-2 strongly correlates to survival in patients with SCLC. Obviously, low IL-2 secretion at the time of diagnosis reduces overall survival. The highly significant correlation between the amount of secreted IL-2 and survival time identifies IL-2 secretion as a new prognostic factor in SCLC. This prognostic factor is independent from other prognostic markers identified so far. It even has identical strong prognostic value compared to these markers, as shown by our statistical analysis.
Among prognostic factors defined in the past, stage of disease, performance status, amount of serum NSE and LDH are considered to have a higher informative value than e.g., age and sex. Thus, extent of disease, NSE, and performance status are so far considered the key factors for the evaluation of the prognosis in SCLC [5] [6] [7] [8] [9] . High interest has been attributed to the identification of such prognostic factors since they influence the choice of therapy. Poor prognosis restricts therapy to palliative treatment, thereby preventing the severe side effects of an aggressive therapy. In patients with a better prognosis, however, aggressive therapy may be initiated [9] .
Compared to established predominant prognostic factors, the amount of IL-2 secretion at diagnosis turned out to be of comparable prognostic value in the multivariate analysis.
These results are based on the investigation of 52 patients. Thus, the possibility remains that we might have selected a subgroup of patients. For example, we did not include in our patients those with low performance status, infections, corticosteroid treatment and other general conditions that might possibly have influenced cytokine secretion. However, as the clinical relevance of predominant prognostic factors identified in larger patient groups in the past has been well confirmed in our group of patients and the prognostic irrelevance of e.g., histologic subtype has been confirmed as well, the possibility of a such a selection of a nonrepresentative subgroup is very unlikely. Nevertheless, our results need to be confirmed with a larger patient population.
Our previous investigations have shown that secretion of cytokines is selectively suppressed in patients with SCLC [1] . Compared to normal controls, immunocompetent cells from patients with SCLC secreted significantly lower amounts of IL-2, IFN-a, IFN-y, and TNF-oc upon mitogen stimulation. Secretion of IL-l-a and IL-l-p was not significantly suppressed. Cytokine secretion substantially improved upon successful reduction of tumor load by chemotherapy but not upon ineffective cytostatic treatment. These results correlate well to our findings that the immunosuppressive factor secreted by SCLC cell lines was transforming growth factor (TGF) pi, a finding that has been confirmed by others [20] . TGF pi induces the same selective cytokine suppression as found in SCLC patients [2, 3] . Thus, the clinical importance of IL-2 secretion in SCLC may be explained on the background of immunoregulatory interactions between tumor cells and immunocompetent cells mediated e.g., by tumor-derived TGF pi. In addition, reconstitution of suppressed cytokine secretion upon reduction of tumor load indicates an interaction between tumor cells and the immune system. Thus, several lines of evidence suggest that TGF pi secreted by tumor cell lines may have clinical relevance in SCLC.
SCLC cell lines can be distuinguished on the basis of their capacity to secrete TGF pi [2] . It remains to be investigated whether in clinical SCLC suppression of IL-2 secretion is also caused by TGF pi secreted by the patients tumor cells. But whatever the causative agent for this suppression of IL-2 secretion may be, this impairment of IL-2 secretion is highly linked to shortened survival. Thus, different subgroups of patients with different survival can be clinically distuinguished by an immunological marker. Moreover, as our clinical findings may be connected to TGF pi-secretion by tumor cells, a model for the immunobiological understanding of the correlation of IL-2 secretion and survival time may exist, that can be studied in further detail.
Finally, our findings may have implications for cytokine therapy. Previous studies with exogenously added cytokines such as IL-2 or interferons showed only marginal effects [21] [22] [23] [24] . Overall response to IL-2 therapy was 21% in one of these previuos reports [24] . Based on our findings, such effects might be improved by a stratification of the treated patient population according to their capacity to secrete IL-2 at the time of diagnosis. In addition, we have previously shown that in SCLC a variety of cytokines were suppressed [2] . Successful substitution therapy might, therefore, comprise defined cytokine cocktails.
